PEG — Pharma Equity A/S Income Statement
0.000.00%
Last trade - 00:00- DKK96.73m
- DKK104.29m
Annual income statement for Pharma Equity A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS/A | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | -4.91 | -3.03 | 20.6 | 21.3 | 17.2 |
| Operating Profit | 4.91 | 3.03 | -20.6 | -21.3 | -17.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 5.39 | 3.48 | -26.6 | -42.4 | -26.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 5.39 | 3.48 | -24.3 | -40.6 | -25.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 5.39 | 3.48 | -24.3 | -40.6 | -25.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 5.39 | 3.48 | -24.3 | -40.6 | -25.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.015 | -0.052 | -0.023 | -0.038 | -0.021 |
| Dividends per Share |